IOVANCE BIOTHERAPEUTICS, INC. Files 8-K
Ticker: IOVA · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, routine-update
TL;DR
IOVANCE BIOTHERAPEUTICS files routine 8-K, no major news.
AI Summary
On August 18, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, incorporated in Delaware, is involved in biological products.
Why It Matters
This 8-K filing indicates a routine update or submission of financial information by IOVANCE BIOTHERAPEUTICS, INC. to the SEC.
Risk Assessment
Risk Level: low — The filing appears to be a standard procedural update without disclosure of significant new risks or material events.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- August 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-36860 (filing_id) — Commission File Number
- 75-3254381 (tax_id) — I.R.S. Employer Identification No.
- Lion Biotechnologies, Inc. (company) — Former Company Name
- Genesis Biopharma, Inc (company) — Former Company Name
- FREIGHT MANAGEMENT CORP (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for IOVANCE BIOTHERAPEUTICS, INC.?
The filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating a routine submission of information to the SEC.
When was the earliest event reported in this filing?
The earliest event reported is dated August 18, 2025.
In which state is IOVANCE BIOTHERAPEUTICS, INC. incorporated?
IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.
What are some of the former names of IOVANCE BIOTHERAPEUTICS, INC. mentioned in the filing?
Former names include Lion Biotechnologies, Inc., Genesis Biopharma, Inc, and FREIGHT MANAGEMENT CORP.
What is the Commission File Number for IOVANCE BIOTHERAPEUTICS, INC.?
The Commission File Number is 001-36860.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 8.8 · Accepted 2025-08-19 16:47:37
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per share IOVA The Nasdaq Stock Marke
Filing Documents
- tm2523802d1_8k.htm (8-K) — 25KB
- tm2523802d1_ex99-1.htm (EX-99.1) — 16KB
- tm2523802d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-25-080304.txt ( ) — 216KB
- iova-20250818.xsd (EX-101.SCH) — 3KB
- iova-20250818_lab.xml (EX-101.LAB) — 33KB
- iova-20250818_pre.xml (EX-101.PRE) — 22KB
- tm2523802d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On August 18, 2025, Iovance Biotherapeutics, Inc. issued a press release announcing the approval of Amtagvi (lifileucel) in Canada for advanced melanoma after anti-PD-1 and targeted therapy. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Iovance Biotherapeutics, Inc., dated August 18, 2025. 104 Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 19, 2025 IOVANCE BIOTHERAPEUTICS, INC. By: /s/ Frederick G. Vogt Frederick G. Vogt, Ph.D., J.D., Interim CEO and President, and General Counsel